CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid... Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition of Aurora kinase.
- Mechanism
- Curator reviewed
Aurora kinases are enzymes that help dividing cells share their materials between two daughter cells. In many people with cancer Aurora kinase malfunctions and normal control of cell division is lost resulting in abnormal growth. CYC116 inhibits Aurora kinase may slow down the growth of cancer cells and lead to their death by apoptosis.
- Primary indication
- Advanced solid tumorsCurator reviewed
- Code names
- CYC116
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with CYC116, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account